Prognostic serum markers in patients with high-grade upper tract urothelial carcinoma

被引:14
作者
Sheth, Kunj R. [1 ]
Haddad, Ahmed Q. [1 ]
Ashorobi, Omotola S. [1 ]
Meissner, Matthew A. [1 ]
Sagalowsky, Arthur I. [1 ]
Lotan, Yair [1 ]
Margulis, Vitaly [1 ]
机构
[1] Univ Texas Southwestern Med Ctr Dallas, Dept Urol, Dallas, TX 75390 USA
关键词
Upper tract urothelial carcinoma; Inflammatory markers; Recurrence-free survival; UPPER URINARY-TRACT; C-REACTIVE PROTEIN; TO-LYMPHOCYTE RATIO; NEOADJUVANT CHEMOTHERAPY; RADICAL NEPHROURETERECTOMY; CELL CARCINOMA; CANCER; SURVIVAL; VALIDATION; OUTCOMES;
D O I
10.1016/j.urolonc.2016.04.009
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: The role of preoperative serum-based markers in predicting survival outcomes of patients has been reported for several cancer types; however, their association with upper tract urothelial carcinoma (UTUC) prognosis is unclear. We evaluated the role of systemic serum-based markers in predicting adverse pathological features and survival outcomes in patients surgically treated for high-grade (HG) UTUC. Methods: We retrospectively reviewed all patients undergoing surgery for HG UTUC between June 2006 and July 2013 at our institution. Comprehensive clinicopathologic data and preoperative serum-based markers including hemoglobin, white blood cell count, platelet count, serum albumin, calcium, and liver function tests were recorded. Associations of serum markers with pathologic features and recurrence-free survival (RFS) were determined by logistic and Cox regression analyses, respectively. The concordance index for the oncologic outcomes model was determined. Results: In total, 101 patients were identified with a median follow-up of 18.5 months (range: 1-74 mo). In all, 60% of patients had pT2 or less and 11% had nodal metastases. Preoperative elevated alkaline phosphatase (ALP) ( >= 116 IU/l) was associated with multiple adverse pathologic features including advanced T stage, lymphovascular invasion, and histologic necrosis. On univariate analysis, serum markers independently associated with RFS included hemoglobin <= 12.9 (hazards ratio [HR] = 2.51; 95% CI: 1.17-5.36, P = 0.018), albumin <= 4 g/dl (HR = 4.4; 95% CI: 2.04-9.30; P < 0.0001), ALP > 116 U/l (HR = 13.3; 95% CI: 5.3-33.52, P < 0.0001), alanine transaminase > 27 (HR = 2.63, 95% CI: 1.11-6.21, P = 0.028), serum aspartate transaminase > 20 (HR = 2.21, 95% CI: 1.04-4.69, P = 0.038), and corrected calcium >= 9.3 (HR = 2.45, 95% CI: 1.01-5.93, P = 0.047). The 2 strongest predictors, albumin and ALP, were combined to form an AA score (range: 0-2), which improved the baseline preoperative clinical model concordance index for prediction of RFS from 0.626 to 0.799. Conclusion: In HG UTUC, elevated preoperative ALP was associated with adverse pathologic features. Additionally, elevated ALP and low albumin were independently associated with worse RFS and overall survival. These serum-based markers are often measured in the preoperative workup of UTUC, and thus they can be included in future prognostic models to risk stratify patients. (C) 2016 Elsevier Inc. All rights reserved.
引用
收藏
页码:418.e9 / 418.e16
页数:8
相关论文
共 41 条
  • [1] Neoadjuvant chemotherapy in invasive bladder cancer:: Update of a systematic review and meta-analysis of individual patient data
    Abol-Enein, H
    Bassi, P
    Boyer, M
    Coppin, CML
    Cortesi, E
    Grossman, HB
    Hall, RR
    Horwich, A
    Malmström, PU
    Martinez-Piñeiro, JA
    Sengelov, L
    Sherif, A
    Wallace, DMA
    Bono, AV
    Goebell, PJ
    Groshen, S
    Torti, FM
    Clarke, NW
    Roberts, JT
    Sylvester, R
    Parmar, MKB
    Stewart, LA
    Tierney, JF
    Vale, CL
    [J]. EUROPEAN UROLOGY, 2005, 48 (02) : 202 - 206
  • [2] Targeting Inflammatory Pathways for Prevention and Therapy of Cancer: Short-Term Friend, Long-Term Foe
    Aggarwal, Bharat B.
    Vijayalekshmi, R. V.
    Sung, Bokyung
    [J]. CLINICAL CANCER RESEARCH, 2009, 15 (02) : 425 - 430
  • [3] The role of chemotherapy in the treatment of urothelial cell carcinoma of the upper urinary tract (UUT-UCC)
    Audenet, Francois
    Yates, David R.
    Cussenot, Olivier
    Roupret, Morgan
    [J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2013, 31 (04) : 407 - 413
  • [4] Prospective Evaluation of Molecular Markers for the Staging and Prognosis of Upper Tract Urothelial Carcinoma
    Bagrodia, Aditya
    Youssef, Ramy F.
    Kapur, Payal
    Darwish, Oussama M.
    Cannon, Chase
    Belsante, Michael J.
    Gerecci, Deniz
    Sagalowsky, Arthur I.
    Shariat, Shahrokh F.
    Lotan, Yair
    Margulis, Vitaly
    [J]. EUROPEAN UROLOGY, 2012, 62 (01) : E27 - E29
  • [5] X-tile: A new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization
    Camp, RL
    Dolled-Filhart, M
    Rimm, DL
    [J]. CLINICAL CANCER RESEARCH, 2004, 10 (21) : 7252 - 7259
  • [6] Degree of hydronephrosis predicts adverse pathological features and worse oncologic outcomes in patients with high-grade urothelial carcinoma of the upper urinary tract
    Chung, Paul H.
    Krabbe, Laura-Maria
    Darwish, Oussama M.
    Westerman, Mary E.
    Bagrodia, Aditya
    Gayed, Bishoy A.
    Haddad, Ahmed Q.
    Kapur, Payal
    Sagalowsky, Arthur I.
    Lotan, Yair
    Margulis, Vitaly
    [J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2014, 32 (07) : 981 - 988
  • [7] Bladder Cancer
    Clark, Peter E.
    Agarwal, Neeraj
    Biagio, Matthew C.
    Eisenberger, Mario A.
    Greenberg, Richard E.
    Herr, Harry W.
    Inman, Brant A.
    Kuban, Deborah A.
    Kuzel, Timothy M.
    Lele, Subodh M.
    Michalski, Jeff
    Pagliaro, Lance C.
    Pal, Sumanta K.
    Patterson, Anthony
    Plimack, Elizabeth R.
    Pohar, Kamal S.
    Porter, Michael P.
    Richie, Jerome P.
    Sexton, Wade J.
    Shipley, William U.
    Small, Eric J.
    Spiess, Philippe E.
    Trump, Donald L.
    Wile, Geoffrey
    Wilson, Timothy G.
    Dwyer, Mary
    Ho, Maria
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2013, 11 (04): : 446 - 475
  • [8] Use of Inflammatory Markers to Guide Cancer Treatment
    Clarke, S. J.
    Chua, W.
    Moore, M.
    Kao, S.
    Phan, V.
    Tan, C.
    Charles, K.
    McMillan, D. C.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 90 (03) : 475 - 478
  • [9] Validation of the pretreatment derived neutrophil-lymphocyte ratio as a prognostic factor in a European cohort of patients with upper tract urothelial carcinoma
    Dalpiaz, O.
    Pichler, M.
    Mannweiler, S.
    Hernandez, J. M. Martin
    Stojakovic, T.
    Pummer, K.
    Zigeuner, R.
    Hutterer, G. C.
    [J]. BRITISH JOURNAL OF CANCER, 2014, 110 (10) : 2531 - 2536
  • [10] The Role of Systemic Chemotherapy in Management of Upper Tract Urothelial Cancer
    Gayed, Bishoy A.
    Thoreson, Gregory R.
    Margulis, Vitaly
    [J]. CURRENT UROLOGY REPORTS, 2013, 14 (02) : 94 - 101